Registration Statement (General Form) — Form S-1
Filing Table of Contents
Document/Exhibit Description Pages Size
1: S-1 Registration Statement (General Form) HTML 1.15M
2: EX-5.1 Opinion of Counsel re: Legality -- exhibit_5-1 HTML 31K
3: EX-10.14 Material Contract -- exhibit_10-14 HTML 40K
4: EX-10.15 Material Contract -- exhibit_10-15 HTML 118K
5: EX-10.16 Material Contract -- exhibit_10-16 HTML 35K
6: EX-10.17 Material Contract -- exhibit_10-17 HTML 68K
7: EX-10.18 Material Contract -- exhibit_10-18 HTML 87K
8: EX-10.19 Material Contract -- exhibit_10-19 HTML 23K
9: EX-23.1 Consent of Experts or Counsel -- exhibit_23-1 HTML 21K
16: R1 Document and Entity Information HTML 33K
17: R2 Consolidated Balance Sheets HTML 93K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
19: R4 Consolidated Statements of Comprehensive Loss HTML 48K
20: R5 Consolidated Statements of Changes in HTML 57K
Shareholders' Equity (Deficiency)
21: R6 Consolidated Statements of Changes in HTML 22K
Shareholders' Equity (Deficiency) (Parenthetical)
22: R7 Consolidated Statements of Cash Flows HTML 105K
23: R8 General HTML 31K
24: R9 Significant Accounting Policies HTML 73K
25: R10 Other Accounts Receivable HTML 34K
26: R11 Property and Equipment, Net HTML 41K
27: R12 Other Accounts Payable HTML 32K
28: R13 Line of Credit HTML 23K
29: R14 Convertible Notes HTML 44K
30: R15 Taxes on Income HTML 67K
31: R16 Contingent Liabilities and Commitments HTML 36K
32: R17 Shareholders' Deficiency HTML 106K
33: R18 Related Parties Balances and Transactions HTML 62K
34: R19 Financial Expenses, Net HTML 37K
35: R20 Basic and Diluted Net Loss Per Share HTML 40K
36: R21 Subsequent Events HTML 37K
37: R22 Significant Accounting Policies (Policies) HTML 118K
38: R23 Significant Accounting Policies (Tables) HTML 33K
39: R24 Other Accounts Receivable (Tables) HTML 30K
40: R25 Property and Equipment, Net (Tables) HTML 39K
41: R26 Other Accounts Payable (Tables) HTML 31K
42: R27 Convertible Notes (Tables) HTML 36K
43: R28 Taxes on Income (Tables) HTML 55K
44: R29 Shareholders' Deficiency (Tables) HTML 75K
45: R30 Related Parties Balances and Transactions (Tables) HTML 44K
46: R31 Financial Expenses, Net (Tables) HTML 37K
47: R32 Basic and Diluted Net Loss Per Share (Tables) HTML 37K
48: R33 General (Narrative) (Details) HTML 44K
49: R34 Significant Accounting Policies (Useful lives of HTML 29K
Property and Equipment) (Details)
50: R35 Significant Accounting Policies (Fair Value HTML 34K
Assumptions For Options Granted) (Details)
51: R36 Other Accounts Receivable (Details) HTML 29K
52: R37 Property and Equipment, Net (Details) HTML 40K
53: R38 Other Accounts Payable (Details) HTML 31K
54: R39 Line of Credit (Details) HTML 32K
55: R40 Convertible Notes (Narrative) (Details) HTML 50K
56: R41 Convertible Notes (Schedule of Convertible Notes) HTML 40K
(Details)
57: R42 Taxes on Income (Narrative) (Details) HTML 36K
58: R43 Taxes on Income (Significant Components of HTML 36K
Deferred Tax Assets) (Details)
59: R44 Taxes on Income (Loss (Income) Before Taxes On HTML 28K
Income) (Details)
60: R45 Taxes on Income (Reconciliation of Beginning and HTML 26K
Ending Unrecognized Tax Benefits) (Details)
61: R46 Contingent Liabilities and Commitments (Other) HTML 33K
(Details)
62: R47 Contingent Liabilities and Commitments HTML 50K
(Compensation Commitments) (Details)
63: R48 Contingent Liabilities and Commitments (Option HTML 24K
Agreement) (Details)
64: R49 Shareholders' Deficiency (Narrative) (Details) HTML 103K
65: R50 Shareholders' Deficiency (Summary of Option HTML 58K
Activity For Employees And Directors) (Details)
66: R51 Shareholders' Deficiency (Summary of Options HTML 41K
Granted to Non-Employees) (Details)
67: R52 Shareholders' Deficiency (Schedule of Share Based HTML 38K
Compensation Expense) (Details)
68: R53 Related Parties Balances and Transactions HTML 83K
(Narrative) (Details)
69: R54 Related Parties Balances and Transactions HTML 37K
(Schedule of Related Party Transactions) (Details)
70: R55 Financial Expenses, Net (Details) HTML 38K
71: R56 Basic and Diluted Net Loss Per Share (Details) HTML 34K
72: R57 Subsequent Events (Details) HTML 76K
74: XML IDEA XML File -- Filing Summary XML 128K
73: EXCEL IDEA Workbook of Financial Reports XLSX 73K
10: EX-101.INS XBRL Instance -- aitb-20161231 XML 1.23M
12: EX-101.CAL XBRL Calculations -- aitb-20161231_cal XML 158K
13: EX-101.DEF XBRL Definitions -- aitb-20161231_def XML 414K
14: EX-101.LAB XBRL Labels -- aitb-20161231_lab XML 770K
15: EX-101.PRE XBRL Presentations -- aitb-20161231_pre XML 635K
11: EX-101.SCH XBRL Schema -- aitb-20161231 XSD 125K
75: ZIP XBRL Zipped Folder -- 0001178913-17-000658-xbrl Zip 116K
‘EX-10.19’ — Material Contract — exhibit_10-19
This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]
Advanced Inhalation Therapies (AIT) Ltd.
2 Derech Meir Weisgal
Rehovot, 7632605 Israel
Via Email
Ron Bentzur, Chairman, AIT
Re: Waiver of Back Salary
Dear Ron:
As you are aware, pursuant to my position as Chief Executive I am entitled to salary of $218,871 annually as of September 2015 (prior annual salary – $195,331). No portion of this salary has been paid from June 2015 through to the present. As such, the total salary owed to me by AIT is presently $304,183 with additional monies due and owing to Dandelion Investments Ltd, in which I am the principal.
As we prepare for the private equity investment and public offering referenced in the Board Resolutions dated
October 21, 2016 and thereafter, and
contingent on the closing of those transactions, please note that I hereby waive, release, discharge and make covenant not to claim any of the earnings referenced herein up to and through the date of the closing on the private equity investment and public offering with salary at the contracted terms to re-commence immediately following the release of funds from the private equity investment. Further contingent on the closing of the referenced transactions, I waive, release, discharge and make covenant not to claim any monies due and owing to Dandelion Investments Ltd., and I am so authorized to issue such waiver.
I acknowledge that I am, upon and subject to the closing of the referenced transactions, waiving substantial rights and earnings on my own behalf and that of Dandelion Investments Ltd., and that I do so voluntarily and without any inducement.
Sincerely,
Advanced Inhalation Therapies (AIT) Ltd.
